Institutional Repository (UniKL IR)
Please use this identifier to cite or link to this item:
http://hdl.handle.net/ir.unikl.edu.my/33969| Title: | Recent progress on small molecule TLR4 antagonist against triple-negative breast cancer progression and complications |
| Authors: | Kathirasan, Darsshen Ramana Siti Nor ’Izzah Normizan Nurul Athirah Mohd Salleh Khor, Poh Yen (UniKL RCMP) |
| Keywords: | Angiogenesis Breast cancer Complication Metastases Myeloid differentiation factor 2 |
| Issue Date: | Dec-2024 |
| Publisher: | Elsevier Ltd |
| Citation: | Kathirasan DR, Siti Nor ’Izzah Normizan, Nurul Athirah Mohd Salleh, Khor, PY. Recent progress on small molecule TLR4 antagonist against triple-negative breast cancer progression and complications. Bioorganic & Medicinal Chemistry [Internet]. 2024 Nov 14;116:118000. Available from: https://doi.org/10.1016/j.bmc.2024.118000 |
| Abstract: | Toll-like receptor 4 (TLR4) plays a vital role in the innate immune response, but its overactivation has been associated with several diseases, such as aggressive progression of triple-negative breast cancer (TNBC). As a result, inhibiting TLR4 has emerged as a potential therapeutic strategy for this challenging breast cancer subtype. This review summarizes recent advancements in the development of small-molecule TLR4 antagonists to suppress TNBC growth, metastasis, and chemotherapy resistance. We also examine their potential in managing cancer-related complications and propose future directions for their application in TNBC therapy. |
| URI: | https://www.sciencedirect.com/science/article/abs/pii/S0968089624004140?via%3Dihub https://ir.unikl.edu.my/jspui/handle/ir.unikl.edu.my/33969 |
| ISSN: | 09680896 |
| Appears in Collections: | Journal Articles |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Recent progress on small molecule TLR4 antagonist against triple-negative breast cancer progression and complications.pdf | 114.58 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.